Correction: using the goal attainment scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

HIGHLIGHTS

• who: Maggie McCue from the Correction to: BMC Psychiatry, (2021) https://doiorg/10.1186/s12888-021-03608, Following the publication of the original article [1], the authors would like to add the graphical abstract. The previous amendment can be found on https://u200bdoi.u200borg/u200b10.u200b, u200bs12888-u200b022-u200b03798-2. The original article [1] has been corrected. Author details , Takeda Pharmaceuticals U.S.A [, ]. Inc., Hayden Lexington, MA, USA. , Lundbeck LLC, Parkway North Blvd, Deerfeld, IL, USA. , University of Michigan Health, E. Medical Center Dr, Ann Arbor, MI, USA. have published the Article: Correction: Using the Goal . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.